A New Targeted Treatment for Patients with a Germline BRCA Mutation: Olaparib in Pancreatic Cancer

References

• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Malvezzi M , BertuccioP, LeviF, LaVecchia C, NegriE. European cancer mortality predictions for the year 2014. Ann. Oncol.25(8), 1650–1656 (2014).
   PubMed Web of Science ®Google Scholar
• Rahib L , SmithBD, AizenbergR, RosenzweigAB, FleshmanJM, MatrisianLM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res.74(11), 2913–2921 (2014).
   PubMed Web of Science ®Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Salvia R , Fernández-DelCastillo C, BassiCet al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann. Surg.239(5), 678 (2004).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Cancer stat facts: cancer of the pancreas. Surveillance: Epidemiology, and End Results Program. (2017). https://seer.cancer.gov/statfacts/html/pancreas.html
   Google Scholar
• Von Hoff DD , ErvinT, ArenaFPet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369(18), 1691–1703 (2013).
   PubMed Web of Science ®Google Scholar
• Conroy T , DesseigneF, YchouMet al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med.364(19), 1817–1825 (2011).
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A , LiC-P, BodokyGet al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase III trial. Lancet387(10018), 545–557 (2016).
   PubMed Web of Science ®Google Scholar
• Bailey P , ChangDK, NonesKet al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature531(7592), 47 (2016).
   PubMed Web of Science ®Google Scholar
• Waddell N , PajicM, PatchAMet al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature518(7540), 495–501 (2015).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415 (2013).
   PubMed Web of Science ®Google Scholar
• Consortium BCL . Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst.91(15), 1310–1316 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson D , EastonDF. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst.94(18), 1358–1365 (2002).
   PubMed Web of Science ®Google Scholar
• Holter S , BorgidaA, DoddAet al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J. Clin. Oncol.33(28), 3124–3129 (2015).
   PubMed Web of Science ®Google Scholar
• Golan T , KindlerHL, ParkJOet al. Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized Phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). J. Clin. Oncol.36(Suppl. 15), 4115 (2018).
   Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Pilié PG , TangC, MillsGB, YapTA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol.16(2), 81–104 (2019).
   PubMed Web of Science ®Google Scholar
• Golan T , KanjiZS, EpelbaumRet al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer111(6), 1132–1138 (2014).
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ , BlaisEM, BrodyJRet al. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the Know Your Tumor Program. JCO Precision Oncol.3, 1–10 (2019).
   PubMedGoogle Scholar
• Dobzhansky TJG . Genetics of natural populations. XIII. Recombination and variability in populations of Drosophilapseudoobscura. 31(3), 269 (1946).
   Google Scholar
• Lord CJ , AshworthA. PARP inhibitors: the first synthetic lethal targeted therapy. Science (New York, NY)355(6330), 1152 (2017).
   Google Scholar
• Bryant HE , SchultzN, ThomasHDet al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature434(7035), 913 (2005).
   PubMed Web of Science ®Google Scholar
• Farmer H , McCabeN, LordCJet al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917 (2005).
   PubMed Web of Science ®Google Scholar
• Yelamos J , FarresJ, LlacunaL, AmpurdanesC, Martin-CaballeroJ. PARP-1 and PARP-2: new players in tumour development. 1(3), 328 (2011).
   Google Scholar
• Murai J , Shar-YinNH, DasBBet al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.72(21), 5588–5599 (2012).
   PubMed Web of Science ®Google Scholar
• Lord CJ , AshworthAJS. PARP inhibitors: the first synthetic lethal targeted therapy. 355(6330), 1152 (2017).
   Google Scholar
• Ceccaldi R , RondinelliB, D’AndreaADJTICB. Repair pathway choices and consequences at the double-strand break. 26(1), 52–64 (2016).
   Google Scholar
• Fong PC , BossDS, YapTAet al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
   PubMed Web of Science ®Google Scholar
• Menear KA , AdcockC, BoulterRet al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J. Med. Chem.51(20), 6581–6591 (2008).
   PubMed Web of Science ®Google Scholar
• Rolfo C , SwaislandH, LeunenKet al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv. Ther.32(6), 510–522 (2015).
   PubMed Web of Science ®Google Scholar
• Evers B , DrostR, SchutEet al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res.14(12), 3916–3925 (2008).
   PubMed Web of Science ®Google Scholar
• Rottenberg S , JaspersJE, KersbergenAet al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci.105(44), 17079–17084 (2008).
   PubMed Web of Science ®Google Scholar
• Fong PC , BossDS, YapTAet al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman B , Shapira-FrommerR, SchmutzlerRKet al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol.33(3), 244–250 (2014).
   PubMedGoogle Scholar
• Golan T , HammelP, ReniMet al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med.381(4), 317 (2019).
   PubMed Web of Science ®Google Scholar
• Heo Y-A , DhillonS. Olaparib tablet: a review in ovarian cancer maintenance therapy. Target. Oncol.13(6), 801–808 (2018).
   PubMed Web of Science ®Google Scholar
• Teresa Macarulla HLK , PascalHammel, MicheleReniet al. Early progression in patients with metastatic pancreatic cancer anda germline BRCA mutation: Phase III Polo trial of olaparib versus placebo. J. Clin. Oncol.38(Suppl. 4), 750 (2020).
   Google Scholar
• Michele Reni HLK , PascalHammel, Ericvan Cutsemet al. Adverse events with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial. J. Clin. Oncol.38(Suppl. 4), 686 (2020).
   PubMed Web of Science ®Google Scholar
• Shroff RT , HendifarA, McwilliamsRRet al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precision Oncol.2, 1–15 (2018).
   PubMed Web of Science ®Google Scholar
• Binder KaR , MickR, O’HaraMet al. A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2, PALB2. Presented at: Cancer Research.GA, USA (2019).
   Google Scholar
• O’reilly EM , LeeJW, LoweryMAet al. Phase I trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer124(7), 1374–1382 (2018).
   PubMed Web of Science ®Google Scholar
• Golan T , VaradhacharyGR, SelaTet al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J. Clin. Oncol.36(Suppl. 4), 297 (2018).
   Web of Science ®Google Scholar
• Nevala-Plagemann C , HidalgoM, Garrido-LagunaI. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol.17, 1–16 (2019).
   Web of Science ®Google Scholar
• Kristeleit R , ShapiroGI, BurrisHAet al. A Phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin. Cancer Res.23(15), 4095–4106 (2017).
   PubMed Web of Science ®Google Scholar
• Swisher EM , LinKK, OzaAMet al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, Phase II trial. Lancet Oncol.18(1), 75–87 (2017).
   PubMed Web of Science ®Google Scholar
• O’reilly EM , LeeJW, ZalupskiMet al. Randomized, multicenter, Phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J. Clin. Oncol.38(13), 1378–1388 (2020).
   PubMed Web of Science ®Google Scholar